When will they be held responsible?

Well, Witty is being cut in terms of his bonus for the year. At the same time, he is getting ONLY a 2.4% raise, while those in R&D are getting a grand 1%. Now tell me, how does this stack up as equitable? It's time for more cuts to the people and compensation at the top.

see
http://www.bloomberg.com/news/articles/2015-02-26/glaxo-chief-witty-s-2014-compensation-dropped-46-as-profit-fell?cmpid=yhoo

 

Sir Andrew had his total compensation cut by ~45% this year. From 7.2 million pounds to 3.9 million pounds.

 

OMG!!! However will he survive on such a paltry sum?

 

Considering the company performance, his bonus should have been no more than 1 pound, with a cut in salary.

 

Now that we've eliminated the key talent in RTP that was clogging the decisions and the system it already seems like there has been an improvement in operational efficiency.

I'd say we're on the right track but might have to come back to chop off a couple more legacy folks.

 

Is it time for Witty et al to go. Past time, IMHO.
http://www.fool.com/investing/general/2015/03/25/is-it-time-for-glaxosmithkline-plc-to-change-manag.aspx#commentsBoxAnchor

 

Past time for Witty to go. Increasing attention to GSK's growing dire situation:

http://www.forbes.com/sites/johnlamattina/2015/05/12/gsks-curious-oncology-research-position-a-recipe-for-failure/?utm_campaign=yahootix&partner=yahootix

http://www.forbes.com/sites/johnlamattina/2015/05/14/is-sir-andrew-witty-the-person-to-lead-a-major-pharmaceutical-company/?utm_campaign=yahootix&partner=yahootix

http://www.ft.com/intl/cms/s/0/823dcc20-f7d9-11e4-8bd5-00144feab7de.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev#axzz3aXscIEGJ

Laughable that they would say Witty as "...popular, even beloved....."

http://www.ft.com/intl/cms/s/2/3a7f8df0-f7b7-11e4-9beb-00144feab7de.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev#axzz3aXscIEGJ

 

So, why is it that GSK make such awful deals. Here is an example of one just announced that would have fit nicely into the GSK portfolio, and would make money too.
http://www.bloomberg.com/news/articles/2015-05-19/johnson-johnson-agrees-to-market-achillion-s-hepatitis-c-drugs?cmpid=yhoo

Why can't GSK management think and act in GSK's purpseful interest to make and sell new and innobative drug as the driver and priority, instead of being interested in themselves, always having to be right, and not consider good science?

 

Witty leaving in 2017, now Mosef S. Both have done much damage, and their departures are long overdue.

http://www.bloomberg.com/news/articles/2016-06-14/glaxo-s-vaccines-unit-chairman-moncef-slaoui-to-retire-next-year?cmpid=yhoo.headline

Is it too long to save the company?

 

Yes, it is.

 

Well folks, the chance to make a big statement about improving Pharma R&D with the choice for a Witty replacement is more and more of business as usual.
http://finance.yahoo.com/news/big-pharma-latest-breakthrough-choosing-150509307.html;_ylt=A0LEVvnyteFXV3IAqB4nnIlQ;_ylu=X3oDMTByMDgyYjJiBGNvbG8DYmYxBHBvcwMyBHZ0aWQDBHNlYwNzYw--
Also a continuation for personal objectives to drive some of the most important corporate decisions: "Glaxo Chairman Philip Hampton is spearheading a government-backed review on how to increase the number of female executives at the U.K.’s biggest 350 companies."